New RSV Vaccine for Older Adults Can Result in Individual and Societal Cost Savings, Benefits

Respiratory syncytial virus (RSV) results in 60,000 to 160,000 hospitalizations and 6,000 to 10,000 deaths of adults 67 and older each year, but newly approved vaccines could make a significant public health and economic impact. In a recent study, U-M researchers evaluated the newly approved vaccines on their cost-effectiveness and efficacy. Contributor David Hutton comments on the findings for the Institute for Healthcare Policy and Innovation.